Eagle Pharmaceuticals, Inc.
EGRX
$1.90
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -10.19% | -29.58% | 214.50% | 24.54% | -121.45% |
| Total Depreciation and Amortization | 0.03% | -1.06% | 42.62% | 115.59% | 61.69% |
| Total Amortization of Deferred Charges | 0.00% | -1.74% | -2.54% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 5.46% | 148.09% | -141.15% | 147.71% | 50.32% |
| Change in Net Operating Assets | 70.38% | -265.09% | 218.99% | -154.71% | 167.99% |
| Cash from Operations | 99.62% | -189.23% | 383.73% | -130.79% | 358.82% |
| Capital Expenditure | 89.66% | -480.00% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -99.92% | 101.67% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | 100.00% | -- | -- |
| Cash from Investing | 99.95% | -139,433.33% | 99.92% | 85.10% | -44,790.48% |
| Total Debt Issued | 0.00% | -76.92% | 333.33% | -- | -- |
| Total Debt Repaid | -1,600.00% | 97.96% | -2,961.80% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -100.00% | -83.53% | -- |
| Repurchase of Common Stock | 85.42% | -7,260.00% | 99.85% | -27,541.67% | 99.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -150.70% | 429.34% | -27.52% | 714.93% | 95.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.42% | -183.69% | 288.58% | 35.75% | -17.14% |